The REPLENISH trial finds secukinumab doubles the remission rate and significantly lowers steroid use in relapsing polymyalgia rheumatica.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/secukinumab-achieves-doubling-remission-rate-and-2026a100061z?src=rss
Author :
Publish date : 2026-02-26 09:16:00
Copyright for syndicated content belongs to the linked Source.